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Abstract Drug-eluting stents (DES) reduce coronary reste-
nosis significantly; however, late stent thrombosis (LST)
occurs, which requires long-term antiplatelet therapy. Angio-
scopic grading of neointimal coverage of coronary stent struts
was established, and itwas revealed thatneointimalformation
is incomplete and prevalence of LST is higher in DES when
compared to bare-metal stents. It was also observed that the
neointima is thicker and LST is less frequent in paclitaxel-
eluting and zotarolimus-eluting stents than in sirolimus-
eluting stents. Many new stents were devised and they are
nowunderexperimentalorclinicalinvestigationstoovercome
the shortcomings of the stents that have been employed
clinically. Endothelial cells are highly anti-thrombotic. Neo-
endothelial cell damage is considered to be caused by friction
between the cells and stent struts due to the thin neointima
between them which might act as a cushion. Therefore,
development of a DES that causes an appropriate thickness
(around 100 μm) of the neointima is a potential option with
which to prevent neo-endothelial cell damage and consequent
LSTwhile preventing restenosis.
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Introduction
Restenosis after stent implantation is an overreaction of the
wound healing response after vascular injury, characterized
by inflammation, granulation, extra-matrix remodeling,
progenitor cell migration and differentiation, and smooth
muscle cell proliferation and migration and their conse-
quent change into connective tissues.
Neointima formation on stent struts is essential for the
vascular wound healing process [1]. Drug-eluting stents
(DES) inhibit the mobilization and differentiation of
progenitor cells of endothelial cells and smooth muscle
cells, and thus not only inhibit restenosis but also impair
neointima formation, which may lead to stent thrombosis.
DES have reduced restenosis significantly, but their
shortcomings became evident, namely insufficient stent
strut coverage by neointima, and consequent late-stent
thrombosis (LST) or very LST, and consequent acute
coronary syndrome that can occur on termination of anti-
thrombotic therapy. This is a typical example of “a new
therapeutic modality that has a new complication.”
To improve the long-term prognosis in the DES era,
development of new DES that accelerate normally func-
tioning neo-endothelial cell formation and cause adequate
smooth muscle and collagen fiber proliferation is required.
Grading of Neointimal Coverage
The thickness of the neointima on the stent struts can be
measuredinμmbyopticalcoherencetomography(OCT),and
it can be assessed by angioscopy based on whether or not the
stent struts can be seen through the neointima. Therefore, the
assessment of neointimal coverage by angioscopy is influ-
enced by the composition of the neointima. Nevertheless,
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DOI 10.1007/s12410-010-9039-3angioscopy is a powerful imaging modality to assess whether
the stent struts are naked (uncovered) or not, the character-
istics of the neointima, and whether a thrombus is formed on
them. Thisimagingmodalitycan clarify the compositionsofa
thrombus: namely red blood cells, platelets and fibrin, and
fresh or old thrombus [2].
Initially, the grade of stent strut coverage by neointima was
angioscopically classified into naked (reflects light, such as
immediately after implantation), seen-through (covered by
neointima but stent struts are visible), and not seen-through
(covered by neointima and stent struts are not visible).
Later, Higo et al. [3￿] and Oyabu et al. [4] classified
neointimal coverage into grade 0 (not covered); grade 1
(covered by a thin layer); and grade 2 (buried under
neointima). Kotani et al. [5] classified neointimal coverage
into four grades: grade 0 (stent struts were exposed); grade
1 (struts bulged into the lumen, although they were covered
by neointima); grade 2 (struts were imbedded but were seen
translucently); and grade 3 (struts were fully embedded and
not visible) (Fig. 1, Table 1). It is still not settled which of
these grading systems is more adequate for evaluation of
neointima.
Comparison of Angioscopy and OCT in Evaluating
Neointimal Coverage
By comparing angioscopy and OCT images in patients,
Tsujimoto [6] observed that stent struts were visible by
angioscopy when the neointimal thickness was within
130 μm by OCT. This study connected angioscopic
neointima grading and exact neointima thickness.
Difference in Neointimal Coverage Between Bare-Metal
Stents and DES
Although restenosis rates have been markedly reduced by
DES, it became evident that stent strut coverage by
neointima was incomplete or much delayed in cases of
DES when compared with bare-metal stents (BMS); stent
struts were covered by neointima in 93% to 100% of
BMS at 6 months [7, 8]; grade 3 neointimal coverage was
seen in 100% of BMS but in only 46% of sirolimus-
eluting stents (SES) at 6 months; and incomplete neo-
intimal coverage was observed even at 2 years after SES
implantation [9].
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Fig. 1 Angioscopic grading
of neointimal coverage of stent
struts, and differences in inci-
dence of each grade and late
stent thrombosis between
zotarolimus-eluting stents (ZES)
and sirolimus-eluting stents
(SES). (Adapted from Kotani
et al. [5]; with permission.)
Table 1 Angioscopic grading of neointimal coverage
Grade 0 Stent struts were exposed
Grade 1 Struts bulged into the lumen, although
they were covered by neointima
Grade 2 Struts were embedded but were seen
translucently
Grade 3 Struts were fully embedded and not
visible
Cited from Kotani et al. [5]
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A w a t ae ta l .[ 10￿￿] observed that 71% of zotarolimus-eluting
stents (ZES) showed grade 3 neointimal coverage, whereas
6% of SES showed grade 3 coverage at 8 months after
deployment. They also observed grades 0 and 1 in SES but
not in ZES [10￿￿]. Similarly, the thickness of neointima in
paclitaxel-eluting stents (PES) was much greater than in SES
[11, 12]. Incomplete neointimal coverage of SES has also
been observed in 11% at 18 months [13].
Since the resolution was reported to be superior to
intravascular ultrasound (IVUS) [14], OCT was used to
evaluate neointimal coverage in DES. Compared with SES,
PES has been found to have a larger neointimal thickness
with fewer uncovered struts [15].
The findings of all of the studies mentioned above
indicate neointimal formation is incomplete or delayed in
SES compared with other DES. However, complete neo-
intimal coverage on SES can be attained by IVUS-guided
optimal sizing of SES [16].
Chieffo et al. [17] obtained neointima by directional
coronary atherectomy from patients, and they found that
smooth muscle phenotype was different among SES, PES,
ZES, and TES (tacrolimus-eluting stent). Wilson et al. [18]
observed in a swine model that persistent para-strut fibrin
deposition was dominant in PES, whereas fibrin deposition
within neointima and medial smooth muscle cell death were
dominant in SES. These histological differences may
participate in different neointima coverage among the DES.
Heterogenicity of Neointimal Coverage in DES
Kim et al. [19] observed by OCT that neointima was more
heterogenous in PES than in SES. Miyoshi et al. [15] also
reported more heterogeneous neointimal formation in PES
compared to SES.
Moore et al. [20] compared polymer-coated rapamycin-
eluting stents and non-polymer–coated rapamycin-eluting
stents by OCT in patients, and they found that neointimal
thickness was less and inhomogeneous in the former. This
finding may suggest that polymers influence neointimal
coverage. Further studies are required on whether regional
differences in neointima thickness are caused by inhomo-
geneous coating of polymer, regional differences in
concentration or release of drugs, or regional differences
in vascular response.
Significance of In-Stent Yellow Plaques
Lesions without yellow color at baseline exhibited yellow
color in 94% of SES-implanted lesions at follow-up of
10 months [3￿]. Higo et al. [21] reported that the yellow
color was due to formation of atherosclerotic neointima and
that “yellow plaque” formation at the stented lesions was
promoted by SES. However, since the in-stent “yellow
plaques” were not examined histologically, the following
other mechanisms may underlie this phenomenon: inflam-
matory cells (macrophages); polymer or polymer degrades
infiltrated into the intima; deposition of β-carotene in these
foreign substances; or organized thrombus.
Peri-Strut Low-Density Area
Miyoshietal.[15] found by OCT that a peri-strut low-density
area was more dominant in PES than in SES. Such a change
has not been observed by angioscopy. Teramoto et al. [22]
reported that peri-strut low-density area in a porcine model
was due to fibrinoid and proteoglycans. It is necessary to
examine whether the same substances or other mechanisms
such as swollen polymers participate in this phenomenon.
Late Stent Thrombosis
Figure 2 shows an example of occlusive late stent
thrombosis (LST) observed in a BMS. A similar occlusive
LST can be formed in DES, resulting in acute coronary
syndrome.
BMS Versus DES (Table 2)
LST was not observed in any patients 6 months after BMS
implantation [23, 24]. The prevalence of LST was com-
Fig. 2 A late stent thrombosis in the left anterior descending artery
6 months after deployment of a bare-metal stent in a 59-year-old man
with ST-elevation myocardial infarction. Arrows indicate stent struts.
The struts were seen through (grade 2 according to grading [5]).
Arrowhead indicates thrombus
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significantly higher in the SES than in BMS (42–86% vs
8–29%) at 6 months after stent implantation [4, 25]. Thus,
LST was less frequent in BMS, probably due to the higher
prevalence of neointimal coverage.
Among DES (Table 2)
Awata et al. [12] observed that LST was more frequently
observed in SES than in PES (43% vs 19%) at 6 months.
They also reported that LST was observed in 31% of
patients in the SES group versus 6% of patients in the ZES
group at 6 months [10￿￿].
Sensitivity of Angioscopy and OCT in Detecting LST
T h r o m b u sw a so b s e r v e di n1 2o f2 4S E Sa n d8o f2 8
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angioscopy [11], indicating that OCT is more sensitive
than angioscopy in detecting LST. One possible reason for
this is that the entire stented lesion can be observed by
OCT, while angioscopic observation is limited to a
confined portion.
Color of In-Stent Structure and LST
Higo et al. [3￿] observed that thrombus was more frequent
on the yellow lesions than on the white lesions of the
stented lesions in the chronic stage. They suggested that
newly formed yellow intima is a potential risk of LST.
Takayama et al. [11] also observed that all LST was
associated with yellow plaque within the stent, and a higher
yellow grade was observed in SES. Thus, they suggested
the characteristics of neointima tissue are different between
SES and PES.
Whether or not yellow matter in the stented lesion is
actually atheromatous plaque, or degraded polymer, or
another substance remains unclear.
Possible Mechanisms of LST and Appropriate
Neointimal Thickening to Prevent Restenosis,
Neo-endothelial Cell Damages, and Consequent LST
Endothelial cells are highly anti-thrombotic. The same may
also be true for neo-endothelial cells regenerated after stent
implantation. Neointima is mainly composed of newly
formed collagen fibers and located between neo-endothelial
cells and stent struts, and acts as a cushion between neo-
endothelial cells and the stent struts.
If the neointima is thin, stent struts are considered to be
dislocated synchronizing to blood pressure changes and
cardiac motion, and accordingly induce mechanical stress
on the neo-endothelial cells.
The struts were seen-through (grade 0–1) by angioscopy
when the neointima thickness was below 130 μm by OCT
in patients [6]. The LST was observed in grade 0 or 1 group
in patients with DES or BMS [10￿￿, 26]. At 6 months after
stenting, neo-endothelial cells were stained in blue with
Evans blue dye, which selectively stains damaged endothe-
lial cells when the neointima thickness grade is 0 to 1
(Fig. 3)[ 26, 27]. In animals, the struts were visible (grade 0
or 1) when the neointimal thickness was around 88 μm, and
LST was frequently observed when the intimal thickness
was within 100 μm[ 26]. All these findings indicated that
neo-endothelial cells were damaged and LST formed on the
struts when neointimal thickness was within approximately
100 μm (Fig. 4).
Fresh LST has been observed in both patients and
animals at 6 months after BMS deployment [26]. It is
conceivable that even if the neo-endothelial cells were
regenerated repeatedly, they were damaged repeatedly by
friction between them and the struts due to luminal blood
pressure changes and cardiac motion, and thus fresh
thrombi were formed repeatedly even at 6 months or later.
Determining exactly how to terminate this “vicious cycle”
is an essential requisite for effective prophylactic treatment
of LST.
LST was also observed when neointimal coverage was
grade 0 or 1 in cases of SES and ZES [10￿￿], as was the
case for BMS [26]. A similar mechanism may underlie LST
in the DES era.
Based on the results in these clinical and animal studies,
the control of neointimal regeneration over 100 μm and
below an appropriate thickness that does not cause
significant restenosis is an essential requisite for the
prevention of LST and restenosis.
New Stents and the Future
Clinically available DES contain rapamycin, sirolimus,
paclitaxel, or zotarolimus. Stent-based release of a selective
Table 2 Incidence of LST by angioscopy
Incidence of LST, %
BMS SES PES ZES
Fujimori et al. [23]0 –––
Tsukahara et al. [24]0 –––
Oyabu et al. [4]8 4 2 ––
Takano et al. [25]2 98 6 ––
Awata et al. [12] – 43 19 –
Awata et al. [10￿￿] – 31 – 6
BMS bare-metal stent, LST late stent thrombosis, PES paclitaxel-
eluting stent, SES sirolimus-eluting stent, ZES zotarolimus-eluting
stent
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has been found to inhibit restenosis in a rabbit model [28].
Polyzene-F–coated stent, which prevents thrombosis, was
also developed [29].
Recently, a DES that releases Evans blue dye slowly was
developed because this dye prevents restenosis even after a
single intracoronary administration [30].
A drug-containing polymer is generally coated on the
stent struts in DES. The polymer and its degraded products
may influence intimal regeneration and neo-endothelial cell
function. A polymer-free leflunomide-eluting stent was
developed, and its efficacy was demonstrated in an animal
model [31￿].
Development of a new anti-thrombotic stent having the
same elasticity as that of the neointima is another option for
preventing LST. The major problems still to be resolved are
as follows: 1) control of the neointima thickness; 2)
acceleration of neo-endothelial cell coverage; and 3)
prevention of neo-endothelial cell damage.
Conclusions
DES reduce coronary restenosis significantly; however,
LST occurs, which requires long-term antiplatelet therapy.
Angioscopic grading of neointimal coverage of coronary
stent struts was established, and it was revealed that
neointimal formation is incomplete and prevalence of LST
is higher in DES when compared to BMS. It was also
observed that the neointima is thicker and LST is less
frequent in PES and ZES than in SES.
Endothelial cells are highly anti-thrombotic. Clinical and
animal studies have revealed that neo-endothelial cells on
stent struts are damaged when the neointima is less than
Thin neointima
≤ 100 ~ 130 μm
Friction between neoendothelial cells 
and struts due to cardiac motion and 
coronary pressure changes
Neoendothelial cell damages and 
loss of anti-thrombotic action
DES: thrombogenicity 
of stent and polymer
Toxic action of drug
Hypercoagulability
Humoral factors
Rheological 
  mechanisms
Stent thrombosis
Fig. 4 Possible mechanisms for damage of the neo-endothelial cells
covering stent struts. DES—drug-eluting stent
Fig. 3 A stented segment of the
left anterior descending artery
6 months after deployment of a
bare-metal stent in a 69-year-old
man with ST-elevation myocar-
dial infarction. a A stent strut
seen through (neointimal cover-
age: grade 2) before (arrow). b
The same stent strut after Evans
blue (arrow). The strut and the
neighboring portions were
stained blue, indicating damages
of not only the neo-endothelial
cells covering the struts but also
those in neighboring portions. c
Stent struts (neointimal coverage
grade 2) distal to a (arrows). d
The same struts (arrows). The
stent struts and the neighboring
portions were stained blue as in
b, indicating extensive neo-
endothelial cell damage
Curr Cardiovasc Imaging Rep (2010) 3:317–323 321100 μm thick, and LST frequently occurs. Neo-endothelial
cell damage is considered to be caused by friction between
the cells and stent struts due to the thin neointima between
them, which might act as a cushion. Therefore, it is
conceivable that controlling neointimal regeneration over
100 μm and below appropriate thickness that does not
cause significant restenosis is necessary to prevent LST.
Also, development of a DES that has the same degree of
elasticity as that of the neointima is a potential option with
which to prevent neo-endothelial cell damage and conse-
quent LST.
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